Logo
Menu
  • Who We Are
  • How We Invest
  • Our Portfolio
    • Abzena
    • Ixlayer
    • Kiniciti
    • PathAI
  • Blog
  • Careers
  • Contact
Biomanufacturing: A Growing Field

Biomanufacturing: A Growing Field

by Biospring | Aug 1, 2022 | Advanced Therapy, Biologics, Biomanufacturing, CDMO, Cell and Gene Therapy, CGT, Drug Development, Life Sciences Technology

For a biotech company, discovering a new therapeutic candidate is a years-long, herculean achievement. A crucial question post-discovery is, can the drug be manufactured at scale? Companies must ensure that they can procure enough of a new therapy for clinical trials...
Our investment in Kiniciti

Our investment in Kiniciti

by Biospring | Apr 26, 2022 | Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Kiniciti

We’re pleased to announce our investment in Kiniciti, a Cell and Gene Therapy (“CGT”) aggregator. We’ve had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market. Biospring’s...
Cell and Gene Therapy 101: A Primer on Advanced Therapies

Cell and Gene Therapy 101: A Primer on Advanced Therapies

by Biospring | Apr 26, 2022 | Biotech, Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Pharma

What if instead of treating the symptoms of a disease, we could target the source of the disease itself? Cell and Gene Therapy (C&GT) can do just that. These advanced therapies are the result of decades of research on the building blocks (cells) and blueprints...

Recent Posts

  • Biospring Partners Welcomes Industry Executives To Its Advisory Board
  • Biomanufacturing: A Growing Field
  • Interview with Zach Weinberg
  • Driving Drug Development with Data Science
  • Proteomics 101

Recent Comments

No comments to show.

Newsletter

Thank you for subscribing!

Subscribe